The day at a glance · 3 min read
Mood · Risk-On
+65
Sentiment, −100 to +100
Merck Q3 Revenue
$18.09B+4.7%
Merck Q3 EPS
$2.49+19.3%
Merck FY Outlook
$67.05B
Key driverStrong Q3 earnings from Merck and Eli Lilly, with raised guidance and blockbuster drug performance
Daily briefHealthcare· Money365.Market AI ·

Big Pharma Earnings Power Thursday Session

Merck and Eli Lilly beat estimates, AbbVie awaits results; pipeline and guidance moves dominate sector.

Big Pharma Earnings Dominate Session

Bullish
01MRK
Merck ($MRK) reported Q3 revenue of $18.09 billion, up 4.7% year on year, and non-GAAP earnings per share of $2.49, beating analyst estimates of $2.09 by 19.3%. The company raised its full-year revenue outlook to approximately $67.05 billion, close to consensus estimates, and increased its 2026 earnings outlook. Shares rose more than 2% in premarket trading Thursday, with the results delivering earnings and revenue surprises of 17.45% and 4.94%, respectively. Wall Street is focusing on the company's newer drugs and pipeline assets as a patent cliff looms for Keytruda, its largest revenue driver.
02LLY
Eli Lilly ($LLY) shares jumped over 4% premarket after the company reported third-quarter results that exceeded analyst expectations and raised its full-year guidance. The beat was driven by strong demand for its diabetes and weight-loss treatments Mounjaro and Zepbound, with the metabolic portfolio powering the results.
03BMY▼ -1.59%
Bristol Myers Squibb ($BMY) reported third-quarter net income of $2 and released its Q3 financial results for 2026 on Thursday. The company is among four Dow dividend payers that topped Wall Street's third-quarter estimates, though their payout stories diverge on yield, coverage, and growth.

Pipeline & Drug Development Updates

Neutral
ABBV
01ABBV
AbbVie ($ABBV) had a mixed week in its pipeline, filing its multiple myeloma drug etentamig with the FDA days after its skin-disease drug lutikizumab beat placebo by just 8 points in a Phase 3 trial. Neither drug is approved, leaving the stock dependent on what the company sells today, with its third-quarter report scheduled for October 30. Market focus is on whether the company's guidance still rises despite the mixed pipeline results.
02
Metaphore Biotechnologies, a Flagship Pioneering company developing antibody medicines designed for the dynamic biology of complex disease, appointed Frank D'Amelio and Pascal Deschatelets, Ph.D., as independent directors to the company's board. The appointments bring scientific and business leadership as Metaphore prepares for clinical development, translating the company's platform into new categories of medicines.

MedTech & Contract Research Activity

Neutral
01TMO▲ +1.61%
Thermo Fisher Scientific ($TMO) has been highlighted as a leading player in the cell and gene therapy contract research organization market. The company is recognized among providers offering integrated clinical trial services for advanced therapies as outsourcing of research and development work expands. The company's role in this segment is tied to rising personalized medicine activity and tighter regulatory compliance demands around complex trials.

Looking Ahead

Neutral
01ABBV
AbbVie ($ABBV) will report Q3 earnings tomorrow before market open, with investors focused on whether the company can maintain its guidance trajectory despite recent pipeline mixed results.
02REGN
Regeneron ($REGN) will announce earnings results tomorrow before market hours, with biotech investors awaiting the company's quarterly performance.
03AMGN▲ +0.87%
Amgen ($AMGN) heads into Q3 earnings with a CFO transition, management warnings about surging costs, and MariTide trials burning through cash. Investors are questioning whether blockbuster growth from Repatha and TEZSPIRE can hold the line on profitability as the company faces rising expenses.

Important Disclaimer — Not Investment Advice

Disclaimer: This article is provided by Money365.Market for general information and educational purposes only. It is not financial advice, a personal recommendation, or an inducement to buy, sell, or invest in any security or product. Capital is at risk and the value of investments can go down as well as up; past performance does not indicate future results. You should seek independent advice from an FCA-authorised adviser before making any financial decision.

Read the full disclaimer — 8 further points, including total-loss risk, our regulatory status and conflicts of interest

Nothing here is an offer or a solicitation to buy or sell anything, and reading it creates no advisory or fiduciary relationship between you and Money365.Market. Any decision you take is your own.

  • You can lose money — including all of it. Individual companies can and do fail, and some of the assets discussed can fall to zero. Only commit money you can afford to lose, and never borrow to invest on the strength of anything you read here.
  • Forecasts are opinion, not fact. Any valuation model, scenario, fair-value range, estimate or other forward-looking statement is illustrative, rests on assumptions that may prove wrong, and is never a price target, a forecast of actual outcomes, or a promise of any return.
  • Published at a point in time. Figures were believed accurate on the publication or last-updated date shown above and are not maintained afterwards; we are under no obligation to update them. Market and company data comes from third-party sources and is provided without warranty of accuracy, completeness or timeliness.
  • Automated content. This brief was compiled by an automated pipeline from validated news and market-data sources and passed through editorial and compliance checks. Automated content can still contain errors — verify anything you intend to rely on.
  • We are not regulated. Money365.Market is not authorised or regulated by the UK Financial Conduct Authority, is not registered with the U.S. Securities and Exchange Commission or FINRA as an investment adviser or broker-dealer, and is not a tax adviser. We hold no licence to give personal financial advice and do not do so.
  • Interests and independence. Money365.Market is not affiliated with, endorsed by or sponsored by any company, fund, exchange or platform mentioned, and is not paid to feature them. The author may hold positions in securities or assets discussed. The site earns revenue from advertising, subscriptions and, where labelled, affiliate links; this does not influence what we publish.
  • Your jurisdiction matters. Tax treatment, contribution limits, product availability and investor protections differ by country and can change. Speak to a qualified tax professional for tax matters, and to a locally licensed adviser if you are outside the UK.

Full terms: Disclaimer · Terms of Service · Privacy Policy